MiMedx Group, Inc $MDXG Shares Bought by First Trust Advisors LP

First Trust Advisors LP lifted its stake in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 50.0% in the 1st quarter, HoldingsChannel.com reports. The fund owned 553,320 shares of the company’s stock after acquiring an additional 184,439 shares during the quarter. First Trust Advisors LP’s holdings in MiMedx Group were worth $2,186,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. SkyView Investment Advisors LLC lifted its stake in MiMedx Group by 3.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after acquiring an additional 3,032 shares in the last quarter. Rafferty Asset Management LLC boosted its position in MiMedx Group by 4.6% during the 4th quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock worth $469,000 after acquiring an additional 3,064 shares during the period. Aviva PLC grew its stake in MiMedx Group by 4.7% during the 4th quarter. Aviva PLC now owns 71,234 shares of the company’s stock valued at $482,000 after acquiring an additional 3,211 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock valued at $559,000 after acquiring an additional 4,049 shares in the last quarter. Finally, AQR Capital Management LLC increased its holdings in shares of MiMedx Group by 42.6% in the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after purchasing an additional 4,296 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MDXG has been the subject of a number of research analyst reports. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 18th. Craig Hallum lowered their price objective on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Wall Street Zen lowered shares of MiMedx Group from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. Finally, Citizens Jmp cut their target price on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research report on Thursday, April 30th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, MiMedx Group has a consensus rating of “Moderate Buy” and an average price target of $8.50.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG opened at $4.34 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. MiMedx Group, Inc has a one year low of $3.03 and a one year high of $7.97. The business’s 50-day moving average price is $3.98 and its two-hundred day moving average price is $4.19. The company has a market capitalization of $632.60 million, a P/E ratio of 108.53 and a beta of 1.45.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). The company had revenue of $64.36 million during the quarter, compared to the consensus estimate of $63.46 million. MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%. Analysts anticipate that MiMedx Group, Inc will post -0.1 earnings per share for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.